**Lymphocytic**
- R/R CD19+ precursor B-lymphoblastic leukemia
- CD3+ acute lymphoma, or poor-risk chronic subtypes of adult T-cell lymphoma leukemia

**Myelogenous**
- AML with wild-type p53 (R/R or front line)
- AML associated with antecedent myeloproliferative disorder
- Mutated AML
- AML (front line therapy)

**Myelodysplastic syndrome**
- MDS or oligoblastic AML

**Hematologic malignancy**
- Hematologic malignancy, not otherwise stated

**Note:** * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: July 13, 2020